de Mendoza Carmen, Valer Luisa, Bacheler Lee, Pattery Theresa, Corral Angélica, Soriano Vincent
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
AIDS. 2006 Apr 24;20(7):1071-4. doi: 10.1097/01.aids.0000222084.44411.cc.
Mutation proI47A has recently been associated with lopinavir/ritonavir (LPV/r) resistance. Only four out of 1859 specimens (0.2%) sent for drug resistance testing (219 drug-naive and 1650 antiretroviral-experienced) showed I47A. All belonged to patients failing LPV/r. The prevalence among protease inhibitor-experienced patients was 0.6%. Phenotypic testing showed that proI47A caused high-level lopinavir resistance (> 100-fold) and cross-resistance to amprenavir, whereas it caused hypersusceptibility to saquinavir. ProI47A should thus be considered the primary lopinavir resistance mutation.
I47A突变最近被认为与洛匹那韦/利托那韦(LPV/r)耐药有关。在送去进行耐药性检测的1859份样本(219份初治患者样本和1650份接受过抗逆转录病毒治疗患者样本)中,只有4份(0.2%)检测出I47A。所有这些样本均来自使用LPV/r治疗失败的患者。在接受过蛋白酶抑制剂治疗的患者中,该突变的发生率为0.6%。表型检测显示,I47A导致高水平的洛匹那韦耐药(>100倍)以及对安普那韦的交叉耐药,而对沙奎那韦敏感。因此,I47A应被视为主要的洛匹那韦耐药突变。